Grünenthal Bond 3.625% 11/26 Soars: Record 2023 Revenue & R&D, Acquisition Investments

• Grünenthal generated €1.8 billion in revenues in 2023, a 10% increase over the prior year
• Adjusted EBITDA was €427 million, a 3% decrease due to increased investments in R&D, acquisitions, and modernizing production facilities
• Grünenthal's R&D pipeline progressed with Phase III development projects of RTX in knee osteoarthritis and Qutenza in post-surgical neuropathic pain
• Grünenthal completed a joint venture collaboration with Kyowa Kirin for its pain brands, owning 51% of the new enterprise Grünenthal Meds
• Strong business performance in the United States, Latin America, and Europe drove revenue growth
• Grünenthal aims to positively impact employees, partners, and society while reducing its environmental footprint.

The price of Grünenthal Unternehmensanleihe 3,625 % bis 11/26 at the time of the news was 98,31EUR and was down -0,11 % compared with the previous day.

Grünenthal Unternehmensanleihe 3,625 % bis 11/26

+0,14 %

+0,16 %

+0,12 %

-0,20 %

+3,76 %

-4,12 %

-3,55 %

-3,55 %

-3,55 %

ISIN:XS2337064856WKN:A3E5QC

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• 3J
• 5J
• 10J
• Max